Sangamo BioSciences unveils collaboration with Biogen


Shares in Sangamo BioSciences (SGMO) jump 15.4% after it announces a partnership with Biogen Idec (BIIB) for the development of new therapies for two inherited blood disorders, sickle cell disease and beta-thalassemia.

Sangamo will receive $20M up front, as much as $300M in milestone payments and royalties.

The companies will use Sangamo's zinc finger nuclease genome-editing technology to address "the abnormal structure or underproduction of hemoglobin" by eliminating a key regulator of gene expression or inserting a corrective gene that will replace a defective one causing disease. (PR)

Sangamo is holding a conference call to discuss the deal.

From other sites
Comments (1)
  • MineMan
    , contributor
    Comments (528) | Send Message
     
    Only the most recent of several deals to come.
    9 Jan 2014, 06:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs